Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024
Rhea-AI Summary
Bioventus (Nasdaq: BVS) has announced it will release its third quarter fiscal year 2024 financial results before market opening on Tuesday, November 5, 2024. The company will host a conference call at 8:30 a.m. Eastern Time on the same day, featuring management discussion of results and business updates. Investors can join via phone at 1-833-636-0497 or watch the live webcast on the company's investor relations website. The webcast recording will remain available for replay until November 4, 2025.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, BVS gained 1.91%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.
To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call.
A live webcast of the call and accompanying materials will also be provided on the “Investor Relations” section of the Company's website at https://ir.bioventus.com/. The webcast will be archived at the same site and available for replay until November 4, 2025.
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
Investor and Media Inquiries:
Dave Crawford
919-474-6787
Dave.Crawford@bioventus.com